NCT07028970 Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
| NCT ID | NCT07028970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing IASO Biotechnology Co., Ltd. |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2024-12-15 |
| Primary Completion | 2040-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2024-12-15 with a primary completion date of 2040-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.
Eligibility Criteria
Inclusion Criteria: \- 1.Received Equecabtagene Autoleucel Injection treatment; 2.For those who participated in pre-marketing clinical studies or post-marketing real-world studies, must have completed or withdrawn from the original study; 3.Voluntary signing of an informed consent form approved by the ethics committee. Exclusion Criteria: * 1\. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.
Contact & Investigator
Jian Li, PhD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT07028970 clinical trial?
This trial is open to participants of all sexes, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07028970 currently recruiting?
Yes, NCT07028970 is actively recruiting participants. Contact the research team at wen.ye@iasobio.com for enrollment information.
Where is the NCT07028970 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Tianjin, China, Tianjin, China and 2 additional locations.
Who is sponsoring the NCT07028970 clinical trial?
NCT07028970 is sponsored by Nanjing IASO Biotechnology Co., Ltd.. The principal investigator is Jian Li, PhD at Peking Union Medical College Hospital. The trial plans to enroll 1,500 participants.